Top Markets
Coin of the day
NeuBase Therapeutics, Inc. NeuBase Therapeutics, Inc.

NeuBase Therapeutics, Inc.

NBSE
株式のランク #39173
Operating as a pre-clinical biopharmaceutical company, NeuBase Therapeutics,... Operating as a pre-clinical biopharmaceutical company, NeuBase Therapeutics, Inc. is dedicated to pioneering therapeutic solutions for rare genetic disorders and various cancers stemming from aberrant genes. At the core of its approach is the proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform. This technology is being utilized to target ailments such as Huntington's disease (HD) and myotonic dystrophy, in addition to a broader spectrum of genetic conditions and applications within oncology. The company's leading therapeutic candidates encompass NT0100, a PATrOL-powered anti-gene therapy for Huntington's disease; NT0200, another PATrOL-enabled anti-gene solution for myotonic dystrophy type 1; and NT0300, a PATrOL-based treatment specifically engineered to address the mutated KRAS gene. NeuBase Therapeutics, Inc. maintains its headquarters in Pittsburgh, Pennsylvania.
株価
$0.378
最終同期: 2024-05-24
時価総額
$618.41K
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 NeuBase Therapeutics, Inc. (NBSE)

カテゴリー

NeuBase Therapeutics, Inc.(NBSE)の株価履歴
終値の最高値: $0.39 (2024-05-01)

終値の最安値: $733.33 (2004-05-01)
NeuBase Therapeutics, Inc. の株価履歴(2004 ~ 2026)
年間株価パフォーマンス
パフォーマンス
2024 -49.90%
2023 -81.22%
2022 -92.72%
2021 -64.02%
2020 7.86%
2019 205.09%
2018 -92.38%
2017 -19.09%
2016 -60.75%
2015 75.31%
2014 6.31%
2013 49.44%
2012 167.16%
2011 169.72%
2010 -59.63%
2009 129.24%
2008 14.29%
2007 -48.15%
2006 -74.29%
2005 -15.32%
2004 0.00%
類似企業または競合の株価
企業 株価 変化率 1年%
$517.18 32.51%
US
$857.76 31.47%
NL
$731.95 7.17%
CH
$1.07K -6.40%
KR
$257.04 13.55%
BE